MedTrace Logo

Personalized Immunotherapy in Adults With Upper Gastrointestinal Tract Cancers

NCT05153304 · Status: WITHDRAWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL

Last updated 2024-06-10

No results posted yet for this study

Summary

The purpose of this study is to determine if it is possible to make and safely administer a 'personalized' cancer vaccine for people diagnosed with an upper gastrointestinal tract cancer.

Conditions

  • Cancer of Gastrointestinal Tract

Interventions

BIOLOGICAL

personalized vaccine

Vaccine will be constructed for each subject that express multiple candidate tumor-derived neoantigens.

DRUG

Nivolumab

3mg/kg nivolumab will be administered intravenous (IV) infusion every 3 weeks for 4 doses. After 4 doses, 480 mg nivolumab will be administered intravenous (IV) infusion every 4 weeks.

Sponsors & Collaborators

Principal Investigators

  • Ezra Cohen, MD · University of California, San Diego

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-06-30
Primary Completion
2026-06-30
Completion
2027-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05153304 on ClinicalTrials.gov